DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,104 filers reported holding DANAHER CORPORATION in Q4 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,809,213 | -0.4% | 15,246 | -0.5% | 0.40% | -5.2% |
Q1 2024 | $3,825,960 | +6.6% | 15,321 | -1.3% | 0.42% | +2.9% |
Q4 2023 | $3,589,471 | +6.9% | 15,516 | +1.6% | 0.41% | -3.3% |
Q3 2023 | $3,357,197 | -54.3% | 15,266 | -50.2% | 0.42% | -5.1% |
Q2 2023 | $7,351,680 | +45.0% | 30,632 | +52.3% | 0.45% | -30.8% |
Q1 2023 | $5,070,036 | -4.6% | 20,116 | +0.5% | 0.65% | -13.4% |
Q4 2022 | $5,312,646 | -99.9% | 20,016 | 0.0% | 0.75% | -0.1% |
Q3 2022 | $5,169,932,000 | +1.9% | 20,016 | 0.0% | 0.75% | +8.2% |
Q2 2022 | $5,074,456,000 | -14.6% | 20,016 | -1.1% | 0.69% | +5.7% |
Q1 2022 | $5,938,759,000 | -10.5% | 20,246 | +0.4% | 0.65% | -7.8% |
Q4 2021 | $6,636,460,000 | +9.2% | 20,171 | +1.0% | 0.71% | -5.8% |
Q3 2021 | $6,079,971,000 | +12.6% | 19,971 | -0.7% | 0.75% | +14.1% |
Q2 2021 | $5,399,671,000 | +18.1% | 20,121 | -1.0% | 0.66% | +7.0% |
Q1 2021 | $4,573,850,000 | +3.0% | 20,321 | +1.6% | 0.62% | +1.0% |
Q4 2020 | $4,441,911,000 | +6.2% | 19,996 | +3.0% | 0.61% | -7.7% |
Q3 2020 | $4,181,923,000 | +21.8% | 19,421 | 0.0% | 0.66% | +10.5% |
Q2 2020 | $3,434,215,000 | +26.9% | 19,421 | -0.6% | 0.60% | +1.0% |
Q1 2020 | $2,705,361,000 | -7.6% | 19,546 | +2.5% | 0.59% | +17.7% |
Q4 2019 | $2,927,017,000 | -47.4% | 19,071 | -50.5% | 0.50% | -3.3% |
Q3 2019 | $5,559,398,000 | +97.0% | 38,492 | +94.9% | 0.52% | -1.3% |
Q2 2019 | $2,822,098,000 | +8.3% | 19,746 | 0.0% | 0.53% | +8.4% |
Q1 2019 | $2,606,866,000 | -33.7% | 19,746 | -48.2% | 0.49% | +14.1% |
Q4 2018 | $3,933,202,000 | +76.0% | 38,142 | +85.4% | 0.43% | +8.7% |
Q3 2018 | $2,235,244,000 | +1.9% | 20,571 | -7.4% | 0.39% | -4.1% |
Q2 2018 | $2,192,768,000 | +0.8% | 22,221 | 0.0% | 0.41% | -0.2% |
Q1 2018 | $2,175,658,000 | -1.7% | 22,221 | -6.8% | 0.41% | -1.4% |
Q4 2017 | $2,213,014,000 | +15.0% | 23,842 | +6.2% | 0.42% | +6.4% |
Q3 2017 | $1,925,074,000 | +6.4% | 22,442 | +4.7% | 0.39% | +2.3% |
Q2 2017 | $1,809,490,000 | -0.4% | 21,442 | +0.9% | 0.38% | -6.6% |
Q1 2017 | $1,816,828,000 | +63.9% | 21,242 | +49.2% | 0.41% | +49.6% |
Q4 2016 | $1,108,597,000 | – | 14,242 | – | 0.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |